Clinical implications of a staging model for bipolar disorders

Expert Review of Neurotherapeutics

Volumn 9, Issue 7, 2009, Pages 957-966

  Kapczinski, Flávio ^a,b   Dias, Vasco Videira ^a,b,c   Kauer Sant'Anna, Marcia ^b   Frey, Benicio Noronha ^d   Grassi Oliveira, Rodrigo ^e   Colom, Francesc ^f   Berk, Michael ^g,h  

^a Hospital de Clinicas de Porto Alegre ^*  (Portugal)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c UNIVERSITY OF EXTREMADURA   (Spain)

^d MCMASTER UNIVERSITY   (Canada)

^e PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^f HOSPITAL CLÍNIC   (Spain)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h ORYGEN RESEARCH CENTRE   (Australia)

Author keywords

Biomarker; Bipolar disorder; Gene environment; Neurocognition; Neuroimaging; Staging; Treatment

Indexed keywords

LITHIUM; MOOD STABILIZER; VALPROATE SEMISODIUM;

ANXIETY DISORDER; BIPOLAR DISORDER; BRAIN SCINTISCANNING; COGNITION; COMORBIDITY; COPING BEHAVIOR; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; EARLY INTERVENTION; HUMAN; INDEPENDENCE; LATENT PERIOD; MEDICAL PERSONNEL; MOOD DISORDER; MORBIDITY; NEUROIMAGING; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREDICTION; PROGNOSIS; REVIEW; RISK FACTOR; TREATMENT PLANNING; TREATMENT RESPONSE;

AGE OF ONSET; ANIMALS; BIPOLAR DISORDER; BRAIN; COGNITION; COMORBIDITY; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; ENVIRONMENT; EXPERT TESTIMONY; HUMANS; PSYCHIATRIC STATUS RATING SCALES;

EID: 67651027316     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.31     Document Type: Review

References (98)

1. Martínez-Arán A, Vieta E, Reinares M et al. Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am. J. Psychiatry 161, 262-270 (2004). (Pubitemid 38419277)
2. Martínez-Arán A, Vieta E, Colom F et al. Cognitive impairment in euthymic bipolar patients: implications for clinical and functional outcome. Bipolar Disord. 6, 224-232 (2004). (Pubitemid 38702298)
3. Martínez-Arán A, Vieta E, Torrent C et al. Functional outcome in bipolar disorders: the role of clinical and cognitive factors. Bipolar Disord. 9, 103-113 (2007). (Pubitemid 46671678)
4. Rosa AR, Sánchez-Moreno J, Martínez-Arán A et al. Validity and reliability of the functioning assessment short test (FAST) in bipolar disorder. Clin. Pract. Epidemol. Ment. Health 7, 3-5 (2007). (Pubitemid 47050102)
5. Kessing LV, Mortensen PB, Bolwig TG. Clinical definitions of sensitisation in affective disorder: a case register study of prevalence and prediction. J. Affect. Disord. 47, 31-39 (1998).
6. Kessing LV, Andersen PK. The effect of episodes on recurrence in affective disorder: a case register study. J. Affect. Disord. 53, 225-231 (1999).
7. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Mania: differential effects of previous depressive and manic episodes on response to treatment. Acta. Psychiatr. Scand. 101, 444-451 (2000).
8. Berk M, Malhi GS, Hallam K et al. Early intervention in bipolar disorders: clinical, biochemical and neuroimaging imperatives. J. Affect. Disord. 114(1-3), 1-13 (2009).
9. Kapczinski F, Vieta E, Andreazza AC et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci. Biobehav. Rev. 32, 675-692 (2008).
10. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int. J. Neuropsychopharmacol. 4, 1-12 (2008).
11. Andreazza AC, Kauer-Sant'Anna M, Frey BN et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J. Affect. Disord. 111, 135-144 (2008).
12. Berk M. Neuroprogression: pathways to progressive brain changes in bipolar disorder. Int. J. Neuropsychopharmacol. 16, 1-5 (2008).
13. Carter CJ. Multiple genes and factors associated with bipolar disorder converge on growth factor and stress activated kinase pathways controlling translation initiation: implications for oligodendrocyte viability. Neurochem. Int. 50, 461-490 (2007).
14. Craddock N, Forty L. Genetics of affective (mood) disorders. Eur. J. Hum. Genet. 14, 660-668 (2006).
15. Serretti A, Mandelli L. The genetics of bipolar disorder: genome 'hot regions,' genes, new potential candidates and future directions. Mol. Psychiatry 13, 742-771 (2008).
16. Caspi A, Moffitt TE. Gene-environment interactions in psychiatry: joining forces with neuroscience. Nat. Rev. Neurosci. 7, 583-590 (2006). (Pubitemid 43995433)
17. Savitz JB, van der Merwe L, Newman TK, Solms M, Stein DJ, Ramesar RS. The relationship between childhood abuse and dissociation. Is it influenced by catechol-O-methyltransferase (COMT) activity? Int. J. Neuropsychopharmacol. 11, 149-161 (2008). (Pubitemid 351231823)
18. Savitz J, van der Merwe L, Stein DJ, Solms M, Ramesar R. Genotype and childhood sexual trauma moderate neurocognitive performance: a possible role for brain-derived neurotrophic factor and apolipoprotein E variants. Biol. Psychiatry 62, 391-399 (2007). (Pubitemid 47284025)
19. Moffitt TE, Caspi A, Rutter M. Strategy for investigating interactions between measured genes and measured environments. Arch. Gen. Psychiatry 62, 473-481 (2005). (Pubitemid 40637222)
20. Bradley RG, Binder EB, Epstein MP et al. Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch. Gen. Psychiatry 65, 190-200 (2008).
21. Miklowitz DJ, Chang KD. Prevention of bipolar disorder in at-risk children: theoretical assumptions and empirical foundations. Dev. Psychopathol. 20, 881-897 (2008).
22. Berk M, Hallam K, Lucas N et al. Early intervention in bipolar disorders: opportunities and pitfalls. Med. J. Aust. 187, S11-S14 (2007).
23. Akiskal HS, Benazzi F. The DSM-IV and ICD-10 categories of recurrent [major] depressive and bipolar II disorders: evidence that they lie on a dimensional spectrum. J. Affect. Disord. 92, 45-54 (2006). (Pubitemid 43668953)
24. Hill SK, Harris MS, Herbener ES, Pavuluri M, Sweeney JA. Neurocognitive allied phenotypes for schizophrenia and bipolar disorder. Schizophr. Bull. 34, 743-759 (2008). (Pubitemid 351957555)
25. McEwen BS, Wingfield JC. The concept of allostasis in biology and biomedicine. Horm. Behav. 43, 2-15 (2003).
26. Post RM. Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci. Biobehav. Rev. 31, 858-873 (2007).
27. Bora E, Yucel M, Pantelis C. Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. J. Affect. Disord. 113(1-2), 1-20 (2009).
28. Grassi-Oliveira R, Daruy-Filho L, Brietzke E. Coping as executive function. Psico 39, 275-281 (2008)
29. Monkul ES, Malhi GS, Soares JC. Anatomical MRI abnormalities in bipolar disorder: do they exist and do they progress? Aust. NZ J. Psychiatry 39, 222-226 (2005).
30. Neves-Pereira M, Mundo E, Muglia P, King N, Macciardi F, Kennedy JL. The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. Am. J. Hum. Genet. 71, 651-655 (2002). (Pubitemid 34970137)
31. Neves-Pereira M, Cheung JK, Pasdar A et al. BDNF gene is a risk factor for a schizophrenia in a Scottish population. Mol. Psychiatry 10, 208-212 (2005). (Pubitemid 40188515)
32. Cunha AB, Frey BN, Andreazza AC et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci. Lett. 398, 215-219 (2006).
33. Machado-Vieira R, Dietrich MO, Leke R et al. Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol. Psychiatry 61, 142-144 (2007). (Pubitemid 46072782)
34. Monteleone P, Serritella C, Martiadis V, Maj M. Decreased levels of serum brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders. Bipolar Disord. 10, 95-100 (2008).
35. Hattiangady B, Rao MS, Shetty GA, Shetty AK. Brain-derived neurotrophic factor, phosphorylated cyclic AMP response element binding protein and neuropeptide Y decline as early as middle age in the dentate gyrus and CA1 and CA3 subfields of the hippocampus. Exp. Neurol. 195, 353-371 (2005). (Pubitemid 41297788)
36. Gooney M, Messaoudi E, Maher FO, Bramham CR, Lynch MA. BDNF-induced LTP in dentate gyrus is impaired with age: analysis of changes in cell signalling events. Neurobiol. Aging 25, 1323-1331 (2004). (Pubitemid 39299170)
37. Yatham LN, Kapczinski F, Andreazza AC et al. Accelerated age-related decrease in brain-derived neurotrophic factor levels in bipolar disorder. Int. J. Neuropsychopharmacol. 12, 137-139 (2009).
38. Kim YK, Jung HG, Myint AM, Kim H, Park SH. Imbalance between proinflammatory and anti-inflammatory cytokines in bipolar disorder. J. Affect. Disord. 104, 91-95 (2007). (Pubitemid 350064526)
39. O'Brien SM, Scully P, Scott LV, Dinan TG. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J. Affect. Disord. 90, 263-267 (2006). (Pubitemid 43183536)
40. Ortiz-Dominguez A, Hernandez ME, Berlanga C et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord. 9, 596-602 (2007). (Pubitemid 47365627)
41. Andreazza AC, Cassini C, Rosa AR et al. Serum S100B and antioxidant enzymes in bipolar patients. J. Psychiatr. Res. 41, 523-529 (2007). (Pubitemid 46227446)
42. Gergerlioglu HS, Savas HA, Bulbul F et al. Changes in nitric oxide level and superoxide dismutase activity during antimanic treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 697-702 (2007). (Pubitemid 46467046)
43. Machado-Vieira R, Andreazza AC, Viale CI et al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci. Lett. 421, 33-36 (2007). (Pubitemid 46908861)
44. Selek S, Savas HA, Gergerlioglu HS et al. The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode. J. Affect. Disord. 107, 89-94 (2008). (Pubitemid 351288914)
45. Savas HA, Gergerlioglu HS, Armutcu F. Elevated serum nitric oxide and superoxide dismutase in euthymic bipolar patients: impact of past episodes. World. J. Biol. Psychiatry 7, 51-55 (2006). (Pubitemid 43878527)
46. Ozcan U, Cao Q, Yilmaz E et al. Endoplasmic reticulum stress links obesity, insulin action, and Type 2 diabetes. Science 306, 457-461 (2004). (Pubitemid 39372439)
47. Ranjekar PK, Hinge A, Hegde MV et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res. 121, 109-122 (2003). (Pubitemid 37500981)
48. Kuloglu M, Ustundag B, Atmaca M et al. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell. Biochem. Funct. 20, 171-175 (2002).
49. Abdalla DS, Monteiro HP, Oliveira JA, Bechara EJ. Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients. Clin. Chem. 32, 805-807 (1986).
50. Mahadik SP, Evans D, Lal H. Oxidative stress and role of antioxidant and W3 essential fatty acid supplementation in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 25, 463-493 (2001). (Pubitemid 32391533)
51. Savas HA, Gergerlioglu HS, Gurel A, Selek S, Savas E, Kocoglu E. Increased xanthine oxidase and malondialdehyde levels in euthymic bipolar patients. Klin. Psikiyatri Derg. 8, 180-185 (2005).
52. Savaş HA, Herken H, Yürekli M et al. Possible role of nitric oxide and adrenomedullin in bipolar affective disorder. Neuropsychobiology 45, 57-61 (2002). (Pubitemid 34224978)
53. Yanik M, Vural H, Tutkun H et al. The role of the arginine-nitric oxide pathway in the pathogenesis of bipolar affective disorder. Eur. Arch. Psychiatry Clin. Neurosci. 254, 43-47 (2004). (Pubitemid 39310548)
54. Reichenberg A, Weiser M, Rabinowitz J et al. A population-based cohort study of premorbid intellectual, language, and behavioral functioning in patients with schizophrenia, schizoaffective disorder, and nonpsychotic bipolar disorder. Am. J. Psychiatry 159, 2027-2035 (2002). (Pubitemid 35423861)
55. Andreazza AC, Kauer-Sant'Anna M, Bond DJ et al. 3-Nitrotyrosine and glutathione antioxidant system in bipolar patients in early and late stage of illness. J. Psychiatry Neurosci. (2009) (In press).
56. Cannon M, Jones P, Gilvarry C et al. Premorbid social functioning in schizophrenia and bipolar disorder: similarities and differences. Am. J. Psychiatry 154, 1544-1550 (1997). (Pubitemid 27471347)
57. Tiihonen J, Haukka J, Henriksson M et al. Premorbid intellectual functioning in bipolar disorder and schizophrenia: results from a cohort study of male conscripts. Am. J. Psychiatry 162, 1904-1910 (2005).
58. Balanzá-Martinez V, Rubio C, Selva-Vera G et al. The neurocognitive endophenotypes (endophenoconitypes) from studies of relatives of bipolar disorder subjects: a systematic review. Neurosci. Biobehav. Rev. 32(8), 1426-1438 (2008).
59. Robinson LJ, Ferrier IN. Evolution of cognitive impairment in bipolar disorder: a systematic review of cross-sectional evidence. Bipolar Disord. 8, 103-116 (2006).
60. Gruber SA, Rosso IM, Yurgelun-Todd D. Neuropsychological performance predicts clinical recovery in bipolar patients. J. Affect. Disord. 105, 253-260 (2008). (Pubitemid 350245684)
61. Torres IJ, Boudreau VG, Yatham LN. Neuropsychological functioning in euthymic bipolar disorder: a meta-analysis. Acta Psychiatr. Scand. 116, 17-26 (2007).
62. Robinson LJ, Thompson JM, Gallagher P et al. A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. J. Affect. Disord. 93, 105-115 (2006). (Pubitemid 43816055)
63. Moorhead TW, McKirdy J, Sussmann JE et al. Progressive gray matter loss in patients with bipolar disorder. Biol. Psychiatry 62, 894-900 (2007). (Pubitemid 47488221)
64. Savitz J, Solms M, Ramesar R. Neuropsychological dysfunction in bipolar affective disorder: a critical opinion. Bipolar Disord. 7, 216-235 (2005). (Pubitemid 40778885)
65. Torres IJ, Boudreau VG, Yatham LN. Neuropsychological functioning in euthymic bipolar disorder: a meta-analysis. Acta. Psychiatr. Scand. Suppl. 434, 17-26 (2007).
66. Kessing LV, Nilsson FM. Increased risk of developing dementia in patients with major affective disorders compared to patients with other medical illnesses. J. Affect. Disord. 73, 261-269 (2003).
67. Phillips ML, Vieta E. Identifying functional neuroimaging biomarkers of bipolar disorder: toward DSM-V. Schizophr. Bull. 33, 893-904 (2007). (Pubitemid 47216661)
68. Koo MS, Levitt JJ, Salisbury DF, Nakamura M, Shenton ME, McCarley RW. A cross-sectional and longitudinal magnetic resonance imaging study of cingulate gyrus gray matter volume abnormalities in first-episode schizophrenia and first-episode affective psychosis. Arch. Gen. Psychiatry 65, 746-760 (2008). (Pubitemid 351957701)
69. Etkin A, Egner T, Peraza DM, Kandel ER, Hirsch J. Resolving emotional conflict: a role for the rostral anterior cingulate cortex in modulating activity in the amygdala. Neuron 51, 871-882 (2006). (Pubitemid 44376825)
70. Pfeifer JC, Welge J, Strakowski SM, Adler CM, DelBello MP. Meta-analysis of amygdala volumes in children and adolescents with bipolar disorder. J. Am. Acad. Child Adolesc. Psychiatry 47, 1289-1298 (2008).
71. Rosso IM, Killgore WD, Cintron CM, Gruber SA, Tohen M, Yurgelun-Todd DA. Reduced amygdala volumes in first-episode bipolar disorder and correlation with cerebral white matter. Biol. Psychiatry 61, 743-749 (2007). (Pubitemid 46330244)
72. Brambilla P, Hatch JP, Soares JC. Limbic changes identified by imaging in bipolar patients. Curr. Psychiatry Rep. 10, 505-509 (2008).
73. Farrow TF, Whitford TJ, Williams LM, Gomes L, Harris AW. Diagnosis-related regional gray matter loss over two years in first episode schizophrenia and bipolar disorder. Biol. Psychiatry 58, 713-723 (2005). (Pubitemid 41547239)
74. Egner T, Etkin A, Gale S, Hirsch J. Dissociable neural systems resolve conflict from emotional versus nonemotional distracters. Cereb. Cortex 18, 1475-1484 (2008). (Pubitemid 351769800)
75. Janssen J, Reig S, Parellada M et al. Regional gray matter volume deficits in adolescents with first-episode psychosis. J. Am. Acad. Child Adolesc. Psychiatry 47, 1311-1320 (2008).
76. Najt P, Nicoletti M, Chen HH et al. Anatomical measurements of the orbitofrontal cortex in child and adolescent patients with bipolar disorder. Neurosci. Lett. 413, 183-186 (2007). (Pubitemid 46209505)
77. Nugent AC, Milham MP, Bain EE et al. Cortical abnormalities in bipolar disorder investigated with MRI and voxel-based morphometry. Neuroimage 30, 485-497 (2006).
78. Versace A, Almeida JR, Hassel S et al. Elevated left and reduced right orbitomedial prefrontal fractional anisotropy in adults with bipolar disorder revealed by tract-based spatial statistics. Arch. Gen. Psychiatry 65, 1041-1052 (2008).
79. Murphy FC, Sahakian BJ, Rubinsztein JS et al. Emotional bias and inhibitory control processes in mania and depression. Psychol. Med. 29, 1307-1321 (1999).
80. Kronhaus DM, Lawrence NS, Williams AM et al. Stroop performance in bipolar disorder: further evidence for abnormalities in the ventral prefrontal cortex. Bipolar Disord. 8, 28-39 (2006).
81. Frey BN, Zunta-Soares GB, Caetano SC et al. Illness duration and total brain gray matter in bipolar disorder: evidence for neurodegeneration? Eur. Neuropsychopharmacol. 18, 717-722 (2008).
82. Lopez-Larson MP, DelBello MP, Zimmerman ME, Schwiers ML, Strakowski SM. Regional prefrontal gray and white matter abnormalities in bipolar disorder. Biol. Psychiatry 52, 93-100 (2002).
83. Lyoo IK, Kim MJ, Stoll AL et al. Frontal lobe gray matter density decreases in bipolar I disorder. Biol. Psychiatry 55, 648-651 (2004).
84. Lyoo IK, Sung YH, Dager SR et al. Regional cerebral cortical thinning in bipolar disorder. Bipolar Disord. 8, 65-74 (2006).
85. Strakowski SM, DelBello MP, Zimmerman ME et al. Ventricular and periventricular structural volumes in first- versus multiple-episode bipolar disorder. Am. J. Psychiatry 159, 1841-1847 (2002).
86. Yatham LN, Lyoo IK, Liddle P, Renshaw PF, Wan D, Lam RW, Hwang J. A magnetic resonance imaging study of mood stabilizer- and neuroleptic-naive first-episode mania. Bipolar Disord. 9, 693-697 (2007). (Pubitemid 350042403)
87. Post RM, Leverich GS, Altshuler LL et al. An overview of recent findings of the Stanley Foundation Bipolar Network (Part I). Bipolar Disord. 5, 310-319 (2003).
88. Franchini L, Zanardi R, Smeraldi E, Gasperini M. Early onset of lithium prophylaxis as a predictor of good long-term outcome. Eur. Arch. Psychiatry Clin. Neurosci. 249, 227-230 (1999). (Pubitemid 29537524)
89. Scott J, Paykel E, Morriss R et al. Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial. Br. J. Psychiatry 188, 313-320 (2006).
90. Sassi RB, Brambilla P, Hatch JP et al. Reduced left anterior cingulate volumes in untreated bipolar patients. Biol. Psychiatry 56, 467-475 (2004). (Pubitemid 39278243)
91. Bearden CE, Thompson PM, Dalwani M et al. Greater cortical gray matter density in lithium-treated patients with bipolar disorder. Biol. Psychiatry 62, 7-16 (2007). (Pubitemid 46898230)
92. Chang K, Barnea-Goraly N, Karchemskiy A et al. Cortical magnetic resonance imaging findings in familial pediatric bipolar disorder. Biol. Psychiatry 58, 197-203 (2005). (Pubitemid 41112267)
93. Goldberg JF, Garno JL, Harrow M. Long-term remission and recovery in bipolar disorder: a review. Curr. Psychiatry Rep. 7, 456-461 (2005). (Pubitemid 43009561)
94. Kauer-Sant'Anna M, Yatham LN, Tramontina J et al. Emotional memory in bipolar disorder. Br. J. Psychiatry. 192, 458-463 (2008).
95. Drevets WC, Savitz J, Trimble M. The subgenual anterior cingulate cortex in mood disorders. CNS Spectr. 13, 663-681 (2008).
96. McGorry PD. Issues for DSM-V: clinical staging: a heuristic pathway to valid nosology and safer, more effective treatment in psychiatry. Am. J. Psychiatry 164, 859-860 (2007).
97. Berk M, Hallam KT, McGorry PD. The potential utility of a staging model as a course specifier: a bipolar disorder perspective. J. Affect. Disord. 100, 279-281 (2007). (Pubitemid 46818451)
98. McGorry PD, Hickie IB, Yung AR et al. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust. NZ J. Psychiatry 40, 616-622 (2006).